Exhibit 99.1

Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities

Singapore – May 20, 2025 – Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that its subsidiary has been awarded a significant contract worth S$375 million by Pancare Technology International (HK) Limited to supply essential healthcare products in Asia-Pacific over the next five years until October 31, 2029. This milestone underscores the Company’s commitment to delivering high-quality medical solutions and strengthening its global presence in the healthcare sector.

As part of the Company’s strategic vision, the Company will be accelerating the integration of AI-powered technologies into its healthcare supply chain operations. This initiative aims to enhance efficiency, optimize logistics, and to ensure the timely delivery of critical medical products to healthcare providers across Asia-Pacific and beyond.

Key Highlights:

“We are honored to secure this contract, which reflects the trust placed in our capabilities,” said Dr Darren Chhoa, CEO of the Company. “Our focus on AI-powered supply chain solutions will ensure reliable, efficient, and scalable healthcare product distribution, benefiting patients and providers alike.”

This achievement aligns the Company’s mission to transform global healthcare through innovation, technology, and sustainable practices.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments. Our operations are based in Singapore, with our clinics being at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an orthopedic service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd

+65 6291 9188

contact@baselmedical.com

www.baselmedical.com

Exhibit 99.2

MASTER SUPPLY AGREEMENT

THIS AGREEMENT (“AGREEMENT”) is made on the 20 day of May 2025.

BETWEEN

PANCARE TECHNOLOGY INTERNATIONAL (HK) LIMITED (“PANCARE”) (Registration No. 75143003), a private company limited by shares, incorporated under the laws of Hong Kong and having its business address at Room 4, 16/F, 2-16 Fa Yuen Street, Mong Kok, Kowloon, Hong Kong (the “BUYER”);

AND

BASEL MEDICAL GROUP PTE LTD (Registration No. 202009227G), a private company limited by shares, incorporated under the laws of Singapore and having its business address at 600 North Bridge Road #12-02/03 Parkview Square Singapore 188778 (the “SELLER”);

Estimated Contract Value: Australian Dollars 450 Million for Five Years till Oct 2029

1. DEFINITIONS & GOVERNANCE

1.1 Key Terms:

“PPE Products”: Goods listed in Schedule A (N95 masks, gloves, gowns, IVD kits, etc.)

“BPJV”: Joint venture entity (if established).

“DDP Sydney”: Delivery Duty Paid to the Australian Department of Health’s warehouse.

“Force Majeure”: Includes pandemics, war, sanctions, or government actions.

1.2 Hierarchy of Documents:

This Agreement controls over Purchase Orders (POs), except for PO-specific terms explicitly overriding this Agreement.

2. SCOPE & ORDER MANAGEMENT

2.1 Procurement & Supply

Basel/BPJV shall procure PPE per Pancare’s specifications and Schedule B (TGA/AS/NZS standards).

Minimum Annual Commitment: AUD 90 million/year (adjustable ±20% with 90-day notice).

2.2 Order Placement

Binding Forecasts: Pancare issues quarterly forecasts; Basel confirms capacity within 72 hours.

Purchase Orders (POs):

Basel must accept/reject POs within 10 business days.

Rejected POs require written justification (e.g., capacity constraints).

2.3 Logistics & Title Transfer

Incoterms: DDP Sydney (Basel covers all logistics, duties, and insurance until delivery) - Title Transfer: Ownership passes to Pancare only upon full payment.

3. FINANCIAL TERMS

3.1 Pricing & Adjustments

Fixed Pricing: Per agreed supplier lists (Schedule C), with annual 3% cap on increases unless input costs rise >5%.

Payment Terms:

Basel advances supplier payments (30-day credit assumed).

Pancare pays Basel’s margin within 5 business days of government payment receipt.

Late Payment Interest: 1.5%/month.

3.2 Financial Security

Performance Bond: AUD 100,000 (initial) + AUD 2 million bank guarantee after AUD 50 million in orders.

Liability Cap: 15% of annual order value for breaches.

4. QUALITY & COMPLIANCE

4.1 Testing & Rejection:

Pre-shipment inspection by SGS/BV at Basel’s cost.

Pancare may reject non-compliant goods; Basel covers replacement costs.

4.2 Regulatory Warranty:

Basel warrants compliance with Australian TGA regulations for 24 months post-delivery.

5. RISK MANAGEMENT

5.1 Force Majeure

30-day suspension for events like pandemics or trade embargoes. Termination permitted if delays exceed 90 days.

5.2 Indemnification

Basel indemnifies Pancare for:

Defective products or late deliveries.

Third-party IP infringement.

6. TERM & TERMINATION

6.1 Term:

5 years (aligned with government contract) or until mutual agreement.

6.2 Termination Triggers:

Material breach (30-day cure period).

Insolvency or failure to meet minimum commitments.

Exit Protocol: Pancare may directly engage Basel’s suppliers post-termination.

7. DISPUTE RESOLUTION

7.1 Escalation:

Level 1: CEO negotiation (14 days).

Level 2: SIAC arbitration (Singapore, expedited rules)

8. MISCELLANEOUS

8.1 Governing Law: Singapore

8.2 Amendments: Written consent required.

8.3 Notices: Email + registered post.

IN WITNESS WHEREOF the Parties have hereunto signed this Agreement on the date first written above.

SCHEDULES:

Schedule A: Product List & Specifications.

Schedule B: Quality Standards (TGA/ISO 13485).

Schedule C: Approved Suppliers & Pricing.

Schedule D: Template Purchase Order.